Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.23.2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Operating expenses:        
Research and development $ 1,005,715 $ 3,229,584 $ 4,515,967 $ 5,132,416
General and administrative 1,894,169 1,635,065 3,354,588 3,670,751
Total operating expenses 2,899,884 4,864,649 7,870,555 8,803,167
Loss from operations (2,899,884) (4,864,649) (7,870,555) (8,803,167)
Other income (expense):        
Change in fair value of financial instruments 606,214 930,193 564,549 2,910,865
Other interest expense (49,182)   (49,182)  
Interest expense on convertible debt   (134,291)   (282,064)
Gain on extinguishment of convertible debt and derivative liability   1,307,421   1,307,421
Other income 30,878 16,288 83,783 27,062
Total other income (expense), net 587,910 2,119,611 599,150 3,963,284
Net loss (2,311,974) (2,745,038) (7,271,405) (4,839,883)
Other comprehensive loss        
Foreign currency translation adjustment (171,462) 1,636 (175,816) 49,477
Comprehensive loss $ (2,483,436) $ (2,743,402) $ (7,447,221) $ (4,790,406)
Net loss per share, basic $ (0.27) $ (0.38) $ (0.85) $ (0.67)
Net loss per share, diluted $ (0.27) $ (0.38) $ (0.85) $ (0.67)
Weighted-average shares outstanding of common shares, basic 8,579,284 7,195,529 8,579,284 7,195,529
Weighted-average shares outstanding of common shares, diluted 8,579,284 7,195,529 8,579,284 7,195,529